Scholarlink

Background <p>Eye movement biomarkers are emerging as promising tools for monitoring neurodegenerative diseases in clinical trials. Saccadic hypometria, the reduced saccade amplitude leading to undershooting visual targets, is a recognized feature of Parkinson’s disease (PD), correlated with motor symptoms severity in cross-sectional studies. However, its use as a biomarker to monitor disease progression has not been studied.</p> Objectives <p>The aim was to assess the sensitivity and reproducibility of saccadic hypometria as a biomarker of PD progression.</p> Methods <p>The amplitude of saccadic hypometria (ASH) was measured in two cohorts: a single-center cohort (SCC) (30 PD patients, 50 healthy&#xa0;controls) followed by a multicenter cohort (MCC) (250 PD patients, 91 healthy&#xa0;controls across 4 sites). Assessments occurred every 3 months over 9 months using a software-based platform (NeuraLight). Motor symptoms were assessed with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. ASH and MDS-UPDRS changes were analyzed using individual slopes of change and compared between groups.</p> Results <p>ASH significantly declined over time in PD patients compared to controls in both cohorts (SCC: − &#xa0;1.96 ± 4.14% vs. 0.33 ± 1.75%, <i>P</i> &lt; 0.01; MCC: − 1.05 ± 3.09% vs. 0.54 ± 1.85%, <i>P</i> &lt; 0.001), and these changes were consistent across MCC sites. MDS-UPDRS III scores remained unchanged over the same period in the SCC, and changes were highly variable across MCC sites, resulting in a non-statistically significant change over time.</p> Conclusion <p>ASH progressively worsened in PD patients over 9 months, even when standard clinical scales showed no significant change. These findings support ASH as a sensitive, objective, and quantitative biomarker for monitoring PD progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changes in Saccadic Hypometria over Time to Monitor Parkinson’s Disease Progression

  • 期刊论文

  • 发表日期：

    2026年5月30日

查看全文
  • Edmund Ben-Ami,
  • Eitan Raveh,
  • Eran Harpaz,
  • Igal Riklin,
  • Tali Band,
  • Tanya Gurevich,
  • Roy N. Alcalay,
  • Pablo Mir,
  • Michelle H. S. Tosin,
  • Christopher G. Goetz,
  • Olivier Rascol

摘要

Background

Eye movement biomarkers are emerging as promising tools for monitoring neurodegenerative diseases in clinical trials. Saccadic hypometria, the reduced saccade amplitude leading to undershooting visual targets, is a recognized feature of Parkinson’s disease (PD), correlated with motor symptoms severity in cross-sectional studies. However, its use as a biomarker to monitor disease progression has not been studied.

Objectives

The aim was to assess the sensitivity and reproducibility of saccadic hypometria as a biomarker of PD progression.

Methods

The amplitude of saccadic hypometria (ASH) was measured in two cohorts: a single-center cohort (SCC) (30 PD patients, 50 healthy controls) followed by a multicenter cohort (MCC) (250 PD patients, 91 healthy controls across 4 sites). Assessments occurred every 3 months over 9 months using a software-based platform (NeuraLight). Motor symptoms were assessed with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. ASH and MDS-UPDRS changes were analyzed using individual slopes of change and compared between groups.

Results

ASH significantly declined over time in PD patients compared to controls in both cohorts (SCC: −  1.96 ± 4.14% vs. 0.33 ± 1.75%, P < 0.01; MCC: − 1.05 ± 3.09% vs. 0.54 ± 1.85%, P < 0.001), and these changes were consistent across MCC sites. MDS-UPDRS III scores remained unchanged over the same period in the SCC, and changes were highly variable across MCC sites, resulting in a non-statistically significant change over time.

Conclusion

ASH progressively worsened in PD patients over 9 months, even when standard clinical scales showed no significant change. These findings support ASH as a sensitive, objective, and quantitative biomarker for monitoring PD progression.